CA2765463C - Methods for treating or preventing fatigue - Google Patents

Methods for treating or preventing fatigue Download PDF

Info

Publication number
CA2765463C
CA2765463C CA2765463A CA2765463A CA2765463C CA 2765463 C CA2765463 C CA 2765463C CA 2765463 A CA2765463 A CA 2765463A CA 2765463 A CA2765463 A CA 2765463A CA 2765463 C CA2765463 C CA 2765463C
Authority
CA
Canada
Prior art keywords
compound
sleep
fatigue
test compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2765463A
Other languages
English (en)
French (fr)
Other versions
CA2765463A1 (en
Inventor
Moise A. Khayrallah
Gary Bream
Stephen E. Butts
Susan Marie Melnick
Duncan Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of CA2765463A1 publication Critical patent/CA2765463A1/en
Application granted granted Critical
Publication of CA2765463C publication Critical patent/CA2765463C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2765463A 2009-06-22 2010-06-21 Methods for treating or preventing fatigue Expired - Fee Related CA2765463C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
US61/219,082 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Publications (2)

Publication Number Publication Date
CA2765463A1 CA2765463A1 (en) 2011-01-13
CA2765463C true CA2765463C (en) 2018-10-09

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2765463A Expired - Fee Related CA2765463C (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Country Status (13)

Country Link
US (5) US8741950B2 (instruction)
EP (1) EP2445490B1 (instruction)
JP (3) JP6095366B2 (instruction)
KR (3) KR102173587B1 (instruction)
CN (2) CN106727486A (instruction)
AU (1) AU2010270971B2 (instruction)
BR (1) BRPI1015233A2 (instruction)
CA (1) CA2765463C (instruction)
IN (1) IN2012DN00624A (instruction)
MX (1) MX2012000034A (instruction)
RU (1) RU2567801C2 (instruction)
TW (1) TWI453014B (instruction)
WO (1) WO2011005473A2 (instruction)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
IN2012DN00624A (instruction) * 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
ES2554459T3 (es) * 2011-12-21 2015-12-21 Innobioscience, Llc Terapia combinada con interferón beta y andrografólidos para la esclerosis múltiple
MX381381B (es) 2013-03-13 2025-03-12 Sk Biopharmaceuticals Co Ltd Tratamiento de cataplejía mediante compuestos de carbamato
WO2015006685A1 (en) * 2013-07-12 2015-01-15 Jazz Pharmaceuticals International Iii Limited Promotion of smoking cessation
DK3021838T3 (da) 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
PL3065751T3 (pl) * 2013-11-08 2020-07-13 Legacy Healthcare Ltd Sposób leczenia raka i chorób współistniejących
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN120574152A (zh) 2016-09-06 2025-09-02 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
CN110139905B (zh) * 2016-12-30 2021-09-28 株式会社东进世美肯 涂层组合物及由此制备的薄膜
CN111201014A (zh) 2017-06-02 2020-05-26 爱尔兰贾兹制药有限公司 治疗过度嗜睡的方法和组合物
MX2020001146A (es) 2017-07-31 2020-08-20 Jazz Pharmaceuticals Ireland Ltd Analogos de carbamoil fenilalaninol y usos de los mismos.
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2022390879A1 (en) * 2021-11-16 2024-06-13 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
AU4567597A (en) 1996-10-08 1998-05-05 Institute Of Child Health Mutant ciita molecule and uses thereof
JP4068154B2 (ja) * 1996-10-10 2008-03-26 エス ケー コーポレイション O―カルバモイル―フェニルアラニノール化合物とその薬剤学的に有用な塩及びその製造方法
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
US8440715B2 (en) * 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
BRPI0520451A2 (pt) 2005-07-26 2009-05-12 Janssen Pharmaceutica Nv métodos para tratamento de distúrbios associados a substáncias quìmicas
EP2079449A2 (en) 2006-10-13 2009-07-22 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
IN2012DN00624A (instruction) * 2009-06-22 2015-06-12 Sk Biopharmaceuticals Co Ltd
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
MX381381B (es) * 2013-03-13 2025-03-12 Sk Biopharmaceuticals Co Ltd Tratamiento de cataplejía mediante compuestos de carbamato
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Also Published As

Publication number Publication date
IN2012DN00624A (instruction) 2015-06-12
JP6368285B2 (ja) 2018-08-01
RU2012101947A (ru) 2013-07-27
JP2015214564A (ja) 2015-12-03
KR20120098578A (ko) 2012-09-05
US9464041B2 (en) 2016-10-11
US8741950B2 (en) 2014-06-03
KR102173587B1 (ko) 2020-11-04
JP2018188450A (ja) 2018-11-29
US10507192B2 (en) 2019-12-17
JP2012530779A (ja) 2012-12-06
MX2012000034A (es) 2012-02-21
EP2445490A4 (en) 2019-10-23
US20140243406A1 (en) 2014-08-28
US20120142769A1 (en) 2012-06-07
CN102481274A (zh) 2012-05-30
BRPI1015233A2 (pt) 2018-02-20
US20170000756A1 (en) 2017-01-05
AU2010270971B2 (en) 2015-08-20
JP6095366B2 (ja) 2017-03-15
WO2011005473A9 (en) 2011-05-12
US20180263950A1 (en) 2018-09-20
TWI453014B (zh) 2014-09-21
WO2011005473A2 (en) 2011-01-13
KR20190105675A (ko) 2019-09-17
TW201105320A (en) 2011-02-16
KR102021075B1 (ko) 2019-11-04
RU2567801C2 (ru) 2015-11-10
EP2445490A2 (en) 2012-05-02
AU2010270971A1 (en) 2012-01-19
US20200061017A1 (en) 2020-02-27
CN106727486A (zh) 2017-05-31
CA2765463A1 (en) 2011-01-13
KR20170086710A (ko) 2017-07-26
EP2445490B1 (en) 2023-02-08
US9999609B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
US10507192B2 (en) Methods for treating or preventing fatigue using O-carbamoyl-phenylalaninol compounds
EP2965756B1 (en) Selective ep4 receptor antagonistic substance for treatment of cancer
EP2349285B1 (en) Nanoemulsions comprising Spicamycin derivatives for use in the treatment of pain
US20160279160A1 (en) Compositions comprising spicamycin derivatives and methods of use thereof
HK1171657A (en) Methods for treating or preventing fatigue
HK1234314A1 (en) Methods for treating or preventing fatigue
US20220125844A1 (en) Opioid antagonists for use in patients using chimeric antigen receptor t and natural killer (nk) cell therapy
HK40003061B (en) Selective ep4 receptor antagonistic substance for treatment of cancer
HK1214763B (en) Selective ep4 receptor antagonistic substance for treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150413

MKLA Lapsed

Effective date: 20210621